Company intelligence / Profile preview

Hoechst Pharmaceuticals

Frankfurt am Main, Hesse, Germany

Ownership: Private
Employees: ~95000
Development stage: Other

Overview

Hoechst developed several first-in-class drugs such as Salvarsan (first effective anti-syphilis drug) and pioneered synthetic dyes, insulin isolation, and analgesics. As of the late 1990s, it had a large commercial portfolio; most R&D had transitioned to subsequent merged entities (Aventis, then Sanofi).

Therapeutic areas: ImmunologyInfectious DiseasesCardiovascularOncologyNeurology
Modalities: Small moleculeChemical drugsBiologic
Industry: Pharma

Partnerships

Rhone-Poulenc (Aventis merger)Schering (Aventis CropScience)Merck (Merial animal health JV)

Beyond the preview

Go deeper on Hoechst Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hoechst Pharmaceuticals.

Explore the full profile